172 results
Page 4 of 9
8-K
EX-99.1
q7u48
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
ne7mfv1 57iv
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
EX-99.1
m3nv0nmt
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
95390
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
e69ool ygc6jhlwos
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
jt3wze3nv30aw4jy
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
uu2jqu
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
EX-1.2
6uy98o ws
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-99.1
ou76ng54ps
6 Aug 20
Adaptimmune Reports Q2 Financial Results and Business Update
7:37am
8-K
EX-99.2
oz5lit9w7yf 8fbh
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
fpbqu109vrus3k
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-1.1
vx84bf72ai7t
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
em3q55qi
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
vq6xa an2yal
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
zinr6zsx
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am